Community Research and Development Information Service - CORDIS

  • European Commission
  • Programmes
  • Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

The scope is to understand:

The utility of β-amyloid imaging in the context of other biomarkers and diagnostic tests in current clinical practise in AD.

The use of β-amyloid imaging in the enrichment of preclinical/pre-dementia clinical trial populations and its incorporation in disease modelling and in adaptive clinical trials.

In-vivo β-amyloid imaging provides information on distribution and severity of one of the two key histo-pathological hallmarks of Alzheimer’s Disease (AD). However its role and value in patient diagnostics/current care pathways as well as its use in patient enrichment in therapeutic trials for pre-clinical/early AD has to be defined yet.

Collecting data and coming to some relevant conclusions on how β-amyloid imaging can aid diagnosis, management and success in preclinical/pre-dementia clinical trials for AD, will facilitate the development of new treatments. It will also improve management, and ultimately quality of life, in patients treated with the drugs available today.

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top